



EUROPEAN
HEMATOLOGY
ASSOCIATION

 **haematologica**

Journal of the European Hematology Association
Owned & published by the Ferrata Storti Foundation

AUTHOR CONTRIBUTION FORM

Title	Vincristine, Dexamethasone and Epratuzumab for Older Relapsed/Refractory CD22+ B-Acute Lymphoblastic Leukemia Patients: a Phase 2 Study.
First author	<i>Patrice Chevallier</i>

According to the International Committee of Medical Journal Editors (ICMJE)

(http://www.icmje.org/ethical_1author.html):

“Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2 and 3. Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship”.

The responsible author of this manuscript confirms that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

Responsible author (<i>author responsible for the integrity of the work as a whole</i>)
Name: Patrice Chevallier
Institute: Hematology Department, CHU, Nantes, France
e-mail: patrice.chevallier@chu-nantes.fr

Author contributions

Please describe the contributions of each author, indicating who was responsible for each part of the study and the preparation of the manuscript (collection of data, experiments, data analysis, generation of figures, interpretation of data, preparation of the text, etc.) :

Patrice Chevallier designed, performed, and coordinated the research, collected, analyzed, interpreted the data, and wrote the manuscript.

Nelly Robillard performed flow cytometry analyses and commented on the manuscript.

Marie-Christine Bene performed statistical analyses, produced the figures, and commented on the manuscript.

William.A. Wegener and David. M. Goldenberg provided epratuzumab, and revised the manuscript.

Françoise Huguët, Emmanuel Raffoux, Anne Etienne, Thibaut Leguay, Françoise Isnard, Thierry Guillaume, Jacques Delaunay, Aude Charbonnier, Arnaud Pigneux, Pierre Peterlin, Herve Dombret included patients, contributed data and commented on the manuscript.

Drs. Wegener and Goldenberg are senior employees with stock or stock options in Immunomedics; Dr. Goldenberg also is a patent inventor of epratuzumab. All other authors declare no potential financial conflicts.